Lipaglyn
✅ Manages lipid levels
✅ Controls blood sugar
✅ Reduces cardiovascular risk
✅ Improves insulin sensitivity
✅ Enhances metabolic health
Lipaglyn contains Saroglitazar.
✓ Orvosi ellenőrzés Morgan Ellis — Gyógyszerkutató · 8 év tapasztalat · Utolsó felülvizsgálat: 2026 május
⚡ Quick Answer — What is Lipaglyn?
Lipaglyn is a brand of saroglitazar (4 mg), a dual PPAR-α/γ agonist developed in India (approved 2013). It is unique: predominantly a PPAR-α agonist (like fibrates) with partial PPAR-γ agonism (like pioglitazone). Used for diabetic dyslipidaemia (elevated triglycerides with type 2 diabetes) and non-alcoholic fatty liver disease (NAFLD/NASH) — approved in India for both indications. Lowers triglycerides by 40–50%, raises HDL, reduces HbA1c by ~0.5 points, and improves liver fat and enzymes. One tablet (4 mg) once daily before food. Does not cause hypoglycaemia. Generally well-tolerated — mild GI upset, rare weight gain. Not a substitute for statins in primary lipid lowering. Avoid in severe hepatic impairment, pregnancy, and known hypersensitivity.
📦 Minden rendelést fedez a Újraküldési Garancia — ha a csomagod nem érkezik meg 20 munkanapon belül, újraküldjük.
Miért rendelj a MedsBase-ról
Generikus gyógyszereink WHO-GMP minősítésű gyártóktól származnak, és diszkrét, egyszerű csomagolásban szállítjuk őket világszerte — a csomagon nem szerepel a gyógyszer neve. A kártyás fizetések egy szabályozott feldolgozón keresztül történnek (a számlaleírások egy szabályozott kártyafizetési feldolgozót tartalmaznak — soha nem “MedsBase” vagy bármilyen gyógyszer neve). Kriptovalutát és SEPA banki átutalást is elfogadunk. Minden rendelést a Reshipment Assurance Policy biztosíték fedez.
What Is Lipaglyn?
Lipaglyn is an oral dual PPAR-α/γ agonist containing saroglitazar (4 mg), developed by Zydus Cadila (India) and approved in India in 2013. Available in packs of 30, 60, 90 or 180 tablets. It is prescribed for:
- Diabetic dyslipidaemia — elevated triglycerides in patients with type 2 diabetes who are not controlled on statins alone
- Hypertriglyceridaemia not adequately controlled by statins
- Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- Primary biliary cholangitis (PBC) — recent indication
Saroglitazar is unique because it is the first dual PPAR-α/γ agonist to reach market. Previous attempts (muraglitazar, tesaglitazar) were abandoned due to safety concerns; saroglitazar’s balanced profile (mostly α, partial γ) appears to avoid them.
How Does Lipaglyn Work?
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that control gene expression in lipid and glucose metabolism. Saroglitazar activates two of them:
- PPAR-α (predominant) — similar to fibrates. Increases fatty-acid oxidation in the liver, lowers triglycerides by 40–50%, modestly raises HDL, and reduces liver fat.
- PPAR-γ (partial) — similar to pioglitazone but weaker. Improves insulin sensitivity in muscle and adipose tissue, reducing HbA1c by ~0.5 percentage points.
The net effect is improvement in both the lipid profile and glycaemic control of diabetic dyslipidaemia in a single tablet. Importantly, because PPAR-γ activation is only partial, the weight gain and fluid-retention seen with pioglitazone are much less common.
Adagolás és alkalmazás
Standard dose: one 4 mg tablet once daily, approximately one hour before food (in the morning).
- Consistent daily timing is recommended.
- Effects on triglycerides are seen within 2–4 weeks; maximum lipid effect at 12 weeks. HbA1c falls over 12–24 weeks.
- Miss a dose — skip it and take the next at the usual time.
- No standard dose adjustment for renal impairment in mild-to-moderate CKD; use with caution in severe impairment.
- Avoid in severe hepatic impairment; check LFTs at baseline and periodically.
Mellékhatások
Saroglitazar is generally well-tolerated.
Gyakori:
- Mild gastric discomfort, dyspepsia, nausea
- Asthenia (mild tiredness)
- Fejfájás
Nem gyakori:
- Mild transaminase elevation (usually dose-related, reversible)
- Slight weight gain (typically < 1 kg; much less than pioglitazone)
- Peripheral oedema (rare, much less than pioglitazone)
No clear signal of heart failure or bladder cancer (unlike pioglitazone). No outcome-trial CV data yet, but the limited trials to date are reassuring.
Gyógyszerkölcsönhatások
- Statins — generally well-tolerated in combination; watch for myopathy.
- Fibrates (other PPAR-α agonists) — avoid combining; overlapping mechanism.
- Varfarin — potential INR change; monitor.
- Insulin and sulfonylureas — hypoglycaemia unlikely with saroglitazar alone, but possible in combination.
- Bile acid sequestrants — may reduce absorption; separate dosing.
Who Should Not Take Lipaglyn?
- Severe hepatic impairment
- Súlyos veseelégtelenség
- Pregnancy and breastfeeding
- Children — safety not established
- Known hypersensitivity to saroglitazar or other PPAR agonists
- Active heart failure — use with caution, though risk appears lower than with pioglitazone
Tárolás
Store Lipaglyn below 30°C in a dry place, in the original blister. Keep out of reach of children.
Gyakran Ismételt Kérdések
How does saroglitazar differ from pioglitazone?
Both are PPAR agonists, but with different selectivity. Pioglitazone is primarily PPAR-γ (strong insulin-sensitiser, weight gain, fluid retention). Saroglitazar is primarily PPAR-α with partial PPAR-γ (strong triglyceride-lowering, modest insulin-sensitising, far less weight gain and oedema). For a patient with diabetic dyslipidaemia, saroglitazar has the stronger lipid effect; for pure insulin resistance with normal lipids, pioglitazone is still more commonly used.
Can Lipaglyn replace my statin?
No — saroglitazar and statins target different lipid abnormalities. Statins lower LDL-cholesterol (the main atherogenic lipid); saroglitazar lowers triglycerides and raises HDL. In diabetic patients with mixed dyslipidaemia, the two are typically used together.
Does Lipaglyn help fatty liver or NASH?
Yes — saroglitazar has approved indications for NAFLD/NASH in India based on Indian trial data showing reductions in ALT, liver fat on MRI-PDFF, and improvement in fibrosis markers. It is one of the few oral treatments with regulatory approval for NASH anywhere.
Does Lipaglyn cause hypoglycaemia?
Not on its own — saroglitazar does not stimulate insulin release. Hypoglycaemia only becomes a concern in combination with a sulfonylurea, meglitinide, or insulin.
Is Lipaglyn approved outside India?
Saroglitazar is approved primarily in India, with some approvals in Mexico and a few other countries. It is not yet approved in the US, EU, UK, or Australia — those agencies have not completed review. Clinically, the drug has been used in over 2 million patient-years in India with a good safety record.
Where can I buy Lipaglyn online?
You can order Lipaglyn (4 mg) from MedsBase in packs of 30, 60, 90 or 180 tablets. We ship worldwide, with discreet packaging and genuine WHO-GMP certified manufacturer stock.
Related Diabetes and Lipid Medications
- Pioz 15 — Pioglitazone (PPAR-γ agonist)
- Jardiance — Empagliflozin (SGLT-2, CV/HF benefit)
- Forxiga — Dapagliflozin (SGLT-2, DAPA-HF)
- Glycomet SR — Metformin sustained-release
- Januvia — Sitagliptin (DPP-4 inhibitor)
- Browse all Diabetes Medications
Kapcsolódó alternatívák
Egyéb termékek a Krónikus betegségek vásárlók által szintén megtekintett termékek:
- Tegrital 100 mg Chewable (Carbamazepine) — Trigeminal Neuralgia & Seizures
- Sertafine
- Wysolone
- Leetrexate
- Novonorm
More options in Diabetes
Rangsorolva a MedsBase legutóbbi rendelési adatai alapján — hogy ebben a kategóriában más vásárlók mit választanak.
| Erősség | 30 tabletta, 60 tabletta, 90 tabletta, 180 tabletta |
|---|
Lipaglyn
Kérdések és válaszok
Lipaglyn
Kapcsolódó termékek
Vélemények
Még nincsenek vélemények